Brief: Burning Rock Received Breakthrough Device Designation From China's NMPA For Its Multi-Cancer Early Detection Test
16/10/2023 24:24
Oct 15 (Reuters) -
* BURNING ROCK RECEIVED BREAKTHROUGH DEVICE DESIGNATION FROM
CHINA’S NMPA FOR ITS MULTI-CANCER EARLY DETECTION TEST
Source text for Eikon: ID:nGNX4MGB06
Further company coverage: BNR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Burning Rock Biotech
See all newsBurning Rock Biotech's Q2 revenue falls, net loss widens on central laboratory weakness
China's Burning Rock Biotech Q1 revenue falls on lower test volumes
China's Burning Rock Biotech Q4 net loss narrows as costs fall
Cancer diagnostics firm Burning Rock Biotech's Q3 revenue rises on pharma R&D growth
Brief: Burning Rock's Oncoguide™ Oncoscreen™ Plus CDX System Now Approved In Japan As A Companion Diagnostic For Capivasertib In Breast Cancer